

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Katherine Meyer Siegler  
 Serial No: 10/644,797  
 Filed: December 17, 2003  
 For: SERUM MACROPHAGE MIGRATION INHIBITORY FACTOR (MIF) AS MARKER FOR PROSTATE CANCER

GAU: 1643  
 Confirmation No. 7390  
 Examiner: Stephen L. Rawlings

**Request For Continued Examination (RCE) Transmittal**

Mail Stop RCE  
 Commissioner for Patents  
 P.O. Box 1450  
 Alexandria, VA 22313-1450

**This is a Request for Continued Examination (RCE) under 37 CFR 1.114 of the above-identified application.**

Request for Continued Examination (RCE) practice under 37 CFR 1.114 does not apply to any utility or plant application filed prior to June 8, 1995, or to any design application. See Instruction Sheet for RCEs (not to be submitted to the USPTO) on page 2.

1. Submission required under 37 C.F.R. § 1.114. Note: If the RCE is proper, any previously filed unentered amendments and amendments enclosed with the RCE will be entered in the order in which they were filed unless applicant instructs otherwise. If applicant does not wish to have any previously filed unentered amendment(s) entered, applicant must request non-entry of such amendment(s).
  - a. ☐ Previously submitted. If a final Office action is outstanding, any amendments filed after the final Office action may be considered as a submission even if this box is not checked.
    - i. ☐ Consider the amendment(s)/reply under 37 C.F.R. § 1.116 previously filed on \_\_\_\_\_
    - ii. ☐ Other: \_\_\_\_\_
  - b. ☒ Enclosed
    - i. ☒ Amendment/Reply
    - ii. ☐ Affidavit(s)/Declaration(s)
    - iii. ☒ Information Disclosure Statement (IDS)
    - iv. ☒ Other: PTO/SB/08b; Cited References (4)
2. Miscellaneous.
  - a. ☐ Suspension of action on the above-identified application is requested under 37 C.F.R. 1.103(c) for a period of \_\_\_\_\_ months. (Period of suspension shall not exceed 3 months; Fee under 37 CFR 1.17(i) required).
  - b. ☐ Other: \_\_\_\_\_
3. Fees. The RCE fee under 37 CFR 1.17(e) is required by 37 CFR 1.114 when the RCE is filed. The Director is hereby authorized to charge the following fees, or credit any overpayments, to:
  - a. ☒ Deposit Account No. 23-2185
    - i. ☐ RCE fee required under 37 C.F.R. 1.17(e)
    - ii. ☐ Extension of time fee (37 CFR 1.136 and 1.17)
    - iii. ☐ Other: \_\_\_\_\_
  - b. ☒ Check in the amount of \$ 790.00 enclosed.
  - c. ☐ Payment by credit card (Form PTO-2038 enclosed).

**WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.**

Blank Rome LLP  
 600 New Hampshire Avenue, N.W.  
 Washington, DC 20037  
 Tel: (202) 772-5800  
 Fax: (202) 572-8398  
 Customer No.: 27557

Date: May 21, 2007

Respectfully submitted,

Charles R. Wolfe, Jr.  
 Registration No. 28,680

05/22/2007 MBERHE 00000017 10644797

790.00 0P